Bulletin
Investor Alert

Sept. 23, 2021, 3:00 a.m. EDT

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    BioVaxys Technology Corp. (BIOV)

or Cancel Already have a watchlist? Log In

James Passin, CEO+1 646 452 7054

Media Contacts BioVaxys Technology Corp.

Gina Cestari, Senior VP 6 Degrees Public Relations+1 917 797 7904gcestari@6degreespr.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/biovaxys-prepares-for-groundbreaking-study-on-reduced-ace2-binding-capabilities-of-hapten-modified-sars-cov-2-proteins-301383613.html

SOURCE BioVaxys Technology Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2021/23/c4873.html

SOURCE: BioVaxys Technology Corp.

COMTEX_393855539/2197/2021-09-23T03:00:00

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2021 CNW Group. All rights reserved.

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.